Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Item
http://www.wikidata.org/entity/Q30396654
Influenza virus vaccines: lessons from the 2009 H1N1 pandemicProgress of small molecular inhibitors in the development of anti-influenza virus agents.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients.Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.The effect of aqueous extract of Xinjiang Artemisia rupestris L. (an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity.Vaccine adjuvants: Why and how.The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age.Pediatric influenza immunization
P2860

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Item
http://www.wikidata.org/entity/Q30396654
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
@ast
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
@en
type
label
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
@ast
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
@en
prefLabel
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
@ast
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921